Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes

Mir, Lluis M.; Gehl, Julie; Serša, Gregor; Collins, Christopher G.; Garbay, Jean-Rémi; Billard, V.; Geertsen, Poul F.; Rudolf, Z; O’Sullivan, Gerald C.; Marty, M.

doi:10.1016/j.ejcsup.2006.08.003

Cited by 527 publications

(535 citation statements)

References 0 publications

Supporting

Mentioning

498

Contrasting

Unclassified

Order By: Relevance

“…All the lesions treated were smaller than 3 cm in diameter. Bleomycin was administered intravenously (15,000 UI/m 2 body surface area) in a time frame of 60 s. The electrical pulses (variable amplitude with 1-5,000 Hz delivery frequencies) were applied to the metastasis in a time window between 8 and 28 min after bleomycin infusion to obtain the optimal response utilizing the most appropriate drug concentrations in tissues, according to previous standardized procedure [1,4].…”

Section: Patients and Human Tissuesmentioning

confidence: 99%

“…ECT treatment is based on the administration of anti-neoplastic drugs, such as bleomycin or cisplatin, followed by the electroporation of the lesions [3]. The electric currents, increasing cell membrane permeability, promote the intracellular concentration of the drug and increase its cytotoxicity [4]. Although the overall objective response rate is high, approximately 80-90 % [1], it is generally accepted that ECT has only local effects, therefore it is currently used as a palliative treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

Gerlini

Sestini

Gennaro

et al. 2012

Clin Exp Metastasis

View full text Add to dashboard Cite

Section: Patients and Human Tissuesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

Gerlini

Sestini

Gennaro

et al. 2012

Clin Exp Metastasis

View full text Add to dashboard Cite

“…ECT is already used in clinical practice for treating metastases of skin melanoma in more than 100 clinical institutions in Europe ) and has already been introduced to clinical trials for treating deep-seated metastases in the liver (Edhemović et al 2011), brain (AgerholmLarsen et al 2011;Linnert et al 2012;Mahmood and Gehl 2011), bone (Fini et al 2011) and soft tissue (Neal et al 2011). While following standard operating procedures (Mir et al 2006) ensures safe and successful treatment of skin melanoma metastases (Marty et al 2006), patient-specific treatment planning is nevertheless required for ECT of deep-seated tumors (Pavliha et al 2012). Namely, deepseated tumors are very diverse in shape, size and location in the body; and long-needle electrodes are used for treating such tumors; therefore, coverage of the whole target tissue (i.e., tumor) with a sufficiently high electric field (which is a prerequisite for successful ECT) (Miklavčič et al 1998(Miklavčič et al , 2006 can currently only be assured by means of numerical modeling of electric field distribution.…”

Section: Introductionmentioning

confidence: 99%

Planning of Electroporation-Based Treatments Using Web-Based Treatment-Planning Software

et al. 2013

View full text Add to dashboard Cite

Electroporation-based treatment combining high-voltage electric pulses and poorly permanent cytotoxic drugs, i.e., electrochemotherapy (ECT), is currently used for treating superficial tumor nodules by following standard operating procedures. Besides ECT, another electroporation-based treatment, nonthermal irreversible electroporation (N-TIRE), is also efficient at ablating deepseated tumors. To perform ECT or N-TIRE of deep-seated tumors, following standard operating procedures is not sufficient and patient-specific treatment planning is required for successful treatment. Treatment planning is required because of the use of individual long-needle electrodes and the diverse shape, size and location of deepseated tumors. Many institutions that already perform ECT of superficial metastases could benefit from treatmentplanning software that would enable the preparation of patient-specific treatment plans. To this end, we have developed a Web-based treatment-planning software for planning electroporation-based treatments that does not require prior engineering knowledge from the user (e.g., the clinician). The software includes algorithms for automatic tissue segmentation and, after segmentation, generation of a 3D model of the tissue. The procedure allows the user to define how the electrodes will be inserted. Finally, electric field distribution is computed, the position of electrodes and the voltage to be applied are optimized using the 3D model and a downloadable treatment plan is made available to the user.

show abstract

“…This temporary permeabilization of the plasma membrane allows genes or drugs entering into the cell cytosol. This technique is very attractive in various applications such as electrochemotherapy Mir et al 2006), cutaneous and subcutaneous tumour nodule treatments (Mir et al 1998), evaluation of the cytotoxicity of nonpermeant or poorly permeant anticancer drugs (Labanauskiene et al 2007), gene electrotransfer to various animal tissues (Andre and Mir 2004;Andre et al 2008) and latterly with in vivo tests (Gothelf and Gehl 2010;Heller and Heller 2006).…”

Section: Introductionmentioning

confidence: 99%

A microfluidic biochip for the nanoporation of living cells

Dalmay

Villemejane

Joubert

et al. 2011

Biosensors and Bioelectronics

Self Cite

View full text Add to dashboard Cite

This paper deals with the development of a microfluidic biochip for the exposure of living cells to nanosecond pulsed electric fields (nsPEF). When exposed to ultra short electric pulses (typical duration of 3 to 10 ns), disturbances on the plasma membrane and on the intra cellular components occur, modifying the behavioral response of cells exposed to drugs or transgene vectors. This phenomenon permits to envision promising therapies. The presented biochip is composed of thick gold electrodes that are designed to deliver a maximum of energy to the biological medium containing cells. The temporal and spectral distributions of the nsPEF are considered for the design of the chip. In order to validate the fabricated biochip ability to orient the pulse towards the cells flowing within the exposition channels, a frequency analysis is provided. High voltage measurements in the time domain are performed to characterize the amplitude and the shape of the nsPEF within the exposition channels and compared to numerical simulations achieved with a 3D Finite-Difference Time-Domain code. We demonstrate that the biochip is adapted for 3 ns and 10 ns pulses and that the nsPEF are homogenously applied to the biological cells regardless their position along the microfluidic channel. Furthermore, biological tests performed on the developed microfluidic biochip permit to prove its capability to permeabilize living cells with nanopulses. To our knowledge, we report here the first successful use of a microfluidic device optimized for the achievement and real time observation of the nanoporation of living cells.

show abstract

Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes

Cited by 527 publications

References 0 publications

Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

Planning of Electroporation-Based Treatments Using Web-Based Treatment-Planning Software

A microfluidic biochip for the nanoporation of living cells

Contact Info

Product

Resources

About